ArticleLancet (London, England)2019

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.

Martin R Gaudinski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.